Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Tuesday. $279.79 million flowed into the stock on the tick-up and $372.20 million flowed out of the stock on the tick-down, for a money net flow of $92.41 million out of the stock. Of all equities tracked, Johnson & Johnson had the 3rd highest net out-flow for the day. Johnson & Johnson traded up $4.67 for the day and closed at $140.79

JNJ has been the topic of a number of research reports. Royal Bank Of Canada reissued a “buy” rating and issued a $138.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 12th. BidaskClub downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 1st. UBS AG reissued a “buy” rating and issued a $148.00 price objective (up previously from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $148.00 price objective on the stock in a research note on Thursday, July 27th. Finally, Credit Suisse Group reissued a “buy” rating on shares of Johnson & Johnson in a research note on Friday, August 4th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and a consensus target price of $135.98.

The firm’s 50-day moving average price is $132.57 and its 200 day moving average price is $130.27. The firm has a market cap of $377.88 billion, a price-to-earnings ratio of 23.82 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the prior year, the company earned $1.68 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

In related news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Harding Loevner LP bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. increased its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares in the last quarter. Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson during the 2nd quarter worth about $124,000. Finally, Harel Insurance Investments & Financial Services Ltd. increased its holdings in Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares in the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Investors Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/17/investors-sell-shares-of-johnson-johnson-jnj-on-strength-jnj-2.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.